Metropolis Healthcare Ltd
NSE:METROPOLIS
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Metropolis Healthcare Ltd
Inventory
Metropolis Healthcare Ltd
Inventory Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Inventory | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
Metropolis Healthcare Ltd
NSE:METROPOLIS
|
Inventory
₹428.1m
|
CAGR 3-Years
4%
|
CAGR 5-Years
7%
|
CAGR 10-Years
N/A
|
|
|
Dr Agarwal's Eye Hospital Ltd
BSE:526783
|
Inventory
₹122.6m
|
CAGR 3-Years
27%
|
CAGR 5-Years
20%
|
CAGR 10-Years
1%
|
|
|
Thyrocare Technologies Ltd
NSE:THYROCARE
|
Inventory
₹379.2m
|
CAGR 3-Years
15%
|
CAGR 5-Years
7%
|
CAGR 10-Years
N/A
|
|
|
Dr. Lal PathLabs Ltd
NSE:LALPATHLAB
|
Inventory
₹502m
|
CAGR 3-Years
-3%
|
CAGR 5-Years
1%
|
CAGR 10-Years
12%
|
|
|
Vijaya Diagnostic Centre Ltd
NSE:VIJAYA
|
Inventory
₹74.1m
|
CAGR 3-Years
9%
|
CAGR 5-Years
22%
|
CAGR 10-Years
N/A
|
|
|
Krsnaa Diagnostics Ltd
NSE:KRSNAA
|
Inventory
₹326.7m
|
CAGR 3-Years
53%
|
CAGR 5-Years
45%
|
CAGR 10-Years
N/A
|
|
Metropolis Healthcare Ltd
Glance View
Metropolis Healthcare Ltd., a pioneer in the diagnostics industry, embarked on its journey in 1980 under the visionary leadership of Dr. Sushil Kanubhai Shah. This Mumbai-based company quickly established itself as a trusted name, offering a comprehensive range of diagnostic services, including pathology tests, radiology, and wellness solutions. The heart of its operations lies in its expansive network of laboratories and collection centers strategically distributed across India and several international locations. By leveraging state-of-the-art technology and maintaining rigorous quality standards, Metropolis has positioned itself as a forerunner in providing precise and reliable medical test results. This was especially crucial as the demand for accurate healthcare diagnostics surged, driven by an increasingly health-conscious population. Metropolis generates its revenue primarily through fees charged for its broad spectrum of diagnostic tests that cater to a variety of health needs, from routine screenings to specialized, high-complexity tests. Its business model capitalizes on partnerships with healthcare providers, hospitals, and corporations, offering customized health packages and diagnostic solutions that ensure a steady flow of clientele. By integrating advanced testing technologies and continuously expanding its service portfolio, the company taps into diverse revenue streams, which include corporate wellness programs and home health services. This diversified approach not only enhances its financial stability but also solidifies its reputation as a go-to healthcare partner for individuals, corporate clients, and healthcare institutions alike.
See Also
What is Metropolis Healthcare Ltd's Inventory?
Inventory
428.1m
INR
Based on the financial report for Dec 31, 2025, Metropolis Healthcare Ltd's Inventory amounts to 428.1m INR.
What is Metropolis Healthcare Ltd's Inventory growth rate?
Inventory CAGR 5Y
7%
Over the last year, the Inventory growth was 15%. The average annual Inventory growth rates for Metropolis Healthcare Ltd have been 4% over the past three years , 7% over the past five years .